Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;47(7):1256-1264.
doi: 10.1111/ced.15175. Epub 2022 May 12.

Tofacitinib in paediatric dermatoses: a narrative review

Ishan Agarwal  1 , Maitreyee Panda  1 , Anupam Das  2
Affiliations
Review

Tofacitinib in paediatric dermatoses: a narrative review

Ishan Agarwal et al. Clin Exp Dermatol. 2022 Jul.

Abstract

Tofacitinib has revolutionized the treatment of numerous dermatological conditions in different age groups. However, evidence for its effectiveness, safety and tolerability in the paediatric population is limited. We performed a literature search, which showed that oral tofacitinib is a reliable option in refractory juvenile dermatomyositis, severe alopecia areata, atopic dermatitis and psoriasis. Topical tofacitinib is an effective option in vitiligo and halo naevus. The risk-benefit ratio should be assessed prior to consideration of this molecule. In this narrative review, we have attempted to present a summary of the evidence of using tofacitinib (oral and topical) in paediatric dermatoses.

PubMed Disclaimer

References

    1. Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 2017; 76: 736-44.
    1. Sonthalia S, Aggarwal P. Oral tofacitinib: contemporary appraisal of its role in dermatology clinical use of oral tofacitinib in skin disorders: an appraisal. Indian Dermatol Online J 2021; 10: 503-18.
    1. Ruperto N, Brunner HI, Zuber Z et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol 2017; 15: 86.
    1. Samadi A, Ahmad Nasrollahi S, Hashemi A et al. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. J Dermatolog Treat 2017; 28: 476-83.
    1. Kerrigan SA, McInnes IB. JAK inhibitors in rheumatology: implications for paediatric syndromes? Curr Rheumatol Rep 2018; 20: 83.